^
BIOMARKER:

CD22 overexpression

i
Other names: CD22, CD22 Molecule, CD22 Antigen, SIGLEC2, Sialic Acid-Binding Ig-Like Lectin 2, B-Lymphocyte Cell Adhesion Molecule, T-Cell Surface Antigen Leu-14, B-Cell Receptor CD22, SIGLEC-2, BL-CAM, Sialic Acid Binding Ig-Like Lectin 2, Siglec-2
Entrez ID:
Related biomarkers:
11ms
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy and Safety by Baseline CD22. (PubMed, Clin Cancer Res)
InO demonstrated a favorable benefit-risk profile versus SC in patients with higher and lower CD22 expression. Patients with high CD22 expression and normal cytogenetics benefited the most from InO therapy.
Clinical • PK/PD data • Journal
|
CD22 (CD22 Molecule)
|
CD22 overexpression • CD22 positive
|
Besponsa (inotuzumab ozogamicin)